Date	e: 6. januar 2023		
You	r name: Niels Kroman		
Mar	nuscript title:	Kirurgisk behandling af bryst	kræft
Mar	nuscript number (if known):	
are re third comr list a	elated to the content of yo parties whose interests ma nitment to transparency ar relationship/activity/intere	ur manuscript. "Related" ay be affected by the cont nd does not necessarily in est, it is preferable that yo	relationships/activities/interests listed below that means any relation with for-profit or not-for-profit tent of the manuscript. Disclosure represents a dicate a bias. If you are in doubt about whether to bu do so.
	uscript only.	o the author's relationship	os/activities/interests as they relate to the <u>current</u>
perta antih In ite	ins to the epidemiology of ypertensive medication, ev	hypertension, you should yen if that medication is n port for the work reported	defined broadly. For example, if your manuscript declare all relationships with manufacturers of ot mentioned in the manuscript. d in this manuscript without time limit. For all months.
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time	e frame: Since the initial plan		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
			 Click TAB in last row to add extra rows
Time	e frame: past 36 months		Silling in last 1911 to day skill fowe
2	Grants or contracts from any entity (if not indicated in item #1 above).	⊠ None	
3	Royalties or licenses	None Non	

4	Consulting fees	⊠ None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None
6	Payment for expert testimony	⊠ None
7	Support for attending meetings and/or travel	None None
8	Patents planned, issued or pending	None None
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None None
11	Stock or stock options	None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None None
13	Other financial or non- financial interests	None None

 \boxtimes I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Date	e: 14. januar 2023		
You	r name: Tove Filtenborg	Tvedskov	
Mar	nuscript title:	Kirurgisk behandling af bryst	kræft
Mar	nuscript number (if known):	
are re third comr list a	elated to the content of yo parties whose interests ma nitment to transparency ar relationship/activity/intere	ur manuscript. "Related" ay be affected by the cont nd does not necessarily in est, it is preferable that yo	relationships/activities/interests listed below that means any relation with for-profit or not-for-profit tent of the manuscript. Disclosure represents a dicate a bias. If you are in doubt about whether to bu do so.
	uscript only.	o the author's relationship	os/activities/interests as they relate to the <u>current</u>
perta antih In ite	ins to the epidemiology of ypertensive medication, ev	hypertension, you should yen if that medication is n port for the work reported	defined broadly. For example, if your manuscript declare all relationships with manufacturers of ot mentioned in the manuscript. d in this manuscript without time limit. For all months.
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time	e frame: Since the initial plan		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
			Click TAB in last row to add extra rows
Time	e frame: past 36 months		Click TAD III last Tow to add extra Tows
11111	e frame. past 50 months		
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None Non	

4	Consulting fees	None Non		
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	□ None Pfizer	Hæfte ombehandling af brystkræft til undervisning	
6	Payment for expert testimony	None Non		
7	Support for attending meetings and/or travel	□ None MSD	San Antonio Breast Cancer Conference 2022	
8	Patents planned, issued or pending	None Non		
9	Participation on a Data Safety Monitoring Board or Advisory Board	□ None MSD	Advisory board om neoadjuverende behandling	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None		
11	Stock or stock options	None Non		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None Non		
13	Other financial or non- financial interests	None Non		

 \boxtimes I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Date	e: 13. januar 2023		
You	r name: Peer Christianse	en	
Mai	nuscript title:	Kirurgisk behandling af bryst	kræft
Mai	nuscript number (if known):	
are re third comr	elated to the content of yo parties whose interests m	ur manuscript. "Related" ay be affected by the cont nd does not necessarily in	relationships/activities/interests listed below that means any relation with for-profit or not-for-profit tent of the manuscript. Disclosure represents a dicate a bias. If you are in doubt about whether to ou do so.
	ollowing questions apply to uscript only.	o the author's relationship	os/activities/interests as they relate to the <u>current</u>
perta antih In ite	nins to the epidemiology of ypertensive medication, ev	hypertension, you should wen if that medication is n port for the work reporte	defined broadly. For example, if your manuscript declare all relationships with manufacturers of ot mentioned in the manuscript. d in this manuscript without time limit. For all months.
0	recins, the time rame for	alsolosare is the past so !	11011111111
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time	e frame: Since the initial plar	whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your
Time	e frame: Since the initial plan All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges,	whom you have this relationship or indicate none (add rows as needed) nning of the work	(e.g., if payments were made to you or to your
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this	whom you have this relationship or indicate none (add rows as needed) nning of the work	(e.g., if payments were made to you or to your
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this	whom you have this relationship or indicate none (add rows as needed) nning of the work	(e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	whom you have this relationship or indicate none (add rows as needed) nning of the work	(e.g., if payments were made to you or to your institution)
Time	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. e frame: past 36 months Grants or contracts from any entity (if not indicated in item #1 above).	whom you have this relationship or indicate none (add rows as needed) nning of the work None	(e.g., if payments were made to you or to your institution)
Time	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated	whom you have this relationship or indicate none (add rows as needed) nning of the work None	(e.g., if payments were made to you or to your institution)

4	Consulting fees	⊠ None		
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or	⊠ None		
		Z None		
	educational events			
6	Payment for expert	⊠ None		
	testimony	△ None		
7	Support for attending	⊠ None		
	meetings and/or travel			
8	Patents planned, issued or	⊠ None		
	pending			
9	Participation on a Data	⊠ None		
	Safety Monitoring Board	Zitone		
	or Advisory Board			
10	Leadership or fiduciary	⊠ None		
	role in other board, society, committee or advocacy group, paid or			
	unpaid			
11	Stock or stock options	None		
12	Receipt of equipment,	⊠ None		
	materials, drugs, medical writing, gifts or other services			
13	Other financial or non- financial interests	⊠ None		

 \boxtimes I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Mani In the are re- third p comm list a r The fo manus The au pertain antihy	interest of transparency, lated to the content of your content to transparency a clated to the content of your content to transparency a clationship/activity/interest of the content to transparency a clationship/activity/interest only. Ithor's relationships/activity to the epidemiology of pertensive medication, en #1 below, report all sup	we ask you to disclose all our manuscript. "Related' lay be affected by the corn of does not necessarily it est, it is preferable that you the author's relationsh wities/interests should be f hypertension, you should ven if that medication is a source."	Il relationships/activities/interests listed below that means any relation with for-profit or not-for-profit need to the manuscript. Disclosure represents a ndicate a bias. If you are in doubt about whether to you do so. ips/activities/interests as they relate to the current defined broadly. For example, if your manuscript declare all relationships with manufacturers of not mentioned in the manuscript.
In the are retained in the formanus The formanus The authorities antihy	interest of transparency, lated to the content of your contines whose interests multiment to transparency a elationship/activity/interestionship questions apply to script only. Author's relationships/activity in the epidemiology of pertensive medication, en #1 below, report all sup	we ask you to disclose all our manuscript. "Related' hay be affected by the core and does not necessarily it est, it is preferable that you the author's relationsh wities/interests should be f hypertension, you should yen if that medication is apport for the work reporter	means any relation with for-profit or not-for-profit of the manuscript. Disclosure represents a ndicate a bias. If you are in doubt about whether to you do so. ips/activities/interests as they relate to the current defined broadly. For example, if your manuscript declare all relationships with manufacturers of not mentioned in the manuscript.
are resthird percommist a reference of the formanus The authoritation antihy	lated to the content of your content whose interests multiment to transparency a elationship/activity/interestions apply to script only. Author's relationships/activity to the epidemiology of pertensive medication, en #1 below, report all support all suppor	our manuscript. "Related' hay be affected by the cor- and does not necessarily in rest, it is preferable that y to the author's relationsh wities/interests should be if hypertension, you should wen if that medication is a	means any relation with for-profit or not-for-profit of the manuscript. Disclosure represents a ndicate a bias. If you are in doubt about whether to you do so. ips/activities/interests as they relate to the current defined broadly. For example, if your manuscript declare all relationships with manufacturers of not mentioned in the manuscript.
manus The au pertair antihy In item	script only. uthor's relationships/activ ns to the epidemiology of pertensive medication, e n #1 below, report all sup	vities/interests should be f hypertension, you shoul ven if that medication is sport for the work reports	Id declare all relationships with manufacturers of not mentioned in the manuscript. ed in this manuscript without time limit. For all
pertain antihy In item	ns to the epidemiology of pertensive medication, e n #1 below, report all sup	f hypertension, you shoul ven if that medication is a port for the work reports	Id declare all relationships with manufacturers of not mentioned in the manuscript. ed in this manuscript without time limit. For all
Julei			
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time	frame: Since the initial plar	nning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	⊠ None	
1.5	No time limit for this item.		
			Click TAB in last row to add extra rows
Time 1	frame: past 36 months	WE HAT THE T	
8	Grants or contracts from any entity (if not indicated in item #1 above).	⊠ None	
3 F	Royalties or licenses	⊠ None	

Consulting fees	⊠ None	
Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or	⊠ None	
educational events		
Payment for expert testimony	⊠ None	
Support for attending meetings and/or travel	⊠ None	
Patents planned, issued or pending	⊠ None	
Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None	
Stock or stock options	⊠ None	
Receipt of equipment, materials, drugs, medical	⊠ None	
writing, gifts or other services		
Other financial or non- financial interests	⊠ None	
	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non-	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, Issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options None None None None None None

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal